ALB and hepatocellular carcinoma: Studies conducted by Ho et al. [88], Ho et al. [89], Ho et al. [90], Chang et al. [91], Ho et al. [92], and Ko et al. [93] demonstrated that a high pre-treatment serum ALB–BIL grade was independently correlated with worse OS in HCC patients treated with curative surgical resection, liver transplantation, radiotherapy, RFA, PEI, TACE, molecular targeted therapy, or supportive care.